Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    23724846 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)
Condition: Cancer, Solid Tumor
Interventions: Drug: Pembrolizumab 1 mg/kg;   Drug: Pembrolizumab 3 mg/kg;   Drug: Pembrolizumab 10 mg/kg;   Drug: Pembrolizumab MEL;   Drug: Pembrolizumab NSCLC;   Drug: Pembrolizumab MEL Low Dose;   Drug: Pembrolizumab MEL High Dose;   Drug: Pembrolizumab NSCLC Low Dose;   Drug: Pembrolizumab NSCLC High Dose;   Drug: Pembrolizumab NSCLC Medium Dose
2 Recruiting Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
Conditions: Unresectable Malignant Neoplasm;   Melanoma;   Metastatic Melanoma;   Stage IV Melanoma;   Stage III Melanoma
Intervention: Drug: Pembrolizumab

Indicates status has not been verified in more than two years